MentionFox
Home › 5%+ stakes › Manufacturing (industry group 38), latest filing in July 2026
5%+ stakes

Manufacturing (industry group 38), latest filing in July 2026

10 companies with 5%+ holders, every filing linked: Anika Therapeutics Inc, Avanos Medical Inc, Hyperfine Inc, Lensar, Inc., Nano-X Imaging Ltd., NeuroOne Medical Technologies Corporation and more. Each section is the company's full record from its filings, newest filings first within each section.

10 companies with 5%+ holders on this page (Manufacturing (industry group 38), latest filing in July 2026), each linked to its filing, starting with Anika Therapeutics Inc, Avanos Medical Inc, Hyperfine Inc. Free check on any of them: https://mentionfox.com/check

On this page

Anika Therapeutics Inc

At 5% or more1
Filings9
Latest filing2026-07-31

Anika Therapeutics Inc has 9 Schedule 13D or 13G filings on record since 2025-10-17. 1 holder's latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.

HolderPercentSharesLatestEvent date
Caligan Partners LP9.95%1,435,130SCHEDULE 13D/A, 2026-01-272026-01-23
Vanguard Capital Management4.95%659,216SCHEDULE 13G/A, 2026-07-312026-06-30
BlackRock Portfolio Management LLC4.1%544,710SCHEDULE 13G/A, 2026-07-172026-06-30
Trigran Investments, Inc.1.2%168,400SCHEDULE 13G/A, 2026-01-082025-12-31
The Vanguard Group0%0SCHEDULE 13G/A, 2026-03-262026-03-13
Reporting personSole votingShared votingSole dispositiveShared dispositiveFiling
Vanguard Capital Management87,1030659,2160SCHEDULE 13G/A, 2026-07-31
BlackRock Portfolio Management LLC520,6220544,7100SCHEDULE 13G/A, 2026-07-17
The Vanguard Group0000SCHEDULE 13G/A, 2026-03-26

The latest filing identifies Anika Therapeutics Inc by CUSIP 035255108 and gives its principal executive office as 32 Wiggins Avenue, Bedford, MA 01730 (SCHEDULE 13G/A, 2026-07-31).

FiledHolderPercentFiling
2025-10-17BlackRock Portfolio Management LLC5.5%SCHEDULE 13G
2025-11-07Trigran Investments, Inc.11.2%SCHEDULE 13G/A
2025-11-21Caligan Partners LP9.95%SCHEDULE 13D/A
2026-01-08Trigran Investments, Inc.1.2%SCHEDULE 13G/A
2026-01-27Caligan Partners LP9.95%SCHEDULE 13D/A
2026-03-26The Vanguard Group0%SCHEDULE 13G/A
2026-04-29Vanguard Capital Management5.19%SCHEDULE 13G
2026-07-17BlackRock Portfolio Management LLC4.1%SCHEDULE 13G/A
2026-07-31Vanguard Capital Management4.95%SCHEDULE 13G/A

Avanos Medical Inc

At 5% or more1
Filings13
Latest filing2026-07-31

Avanos Medical Inc has 13 Schedule 13D or 13G filings on record since 2025-07-29. 1 holder's latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.

HolderPercentSharesLatestEvent date
Vanguard Capital Management5%2,344,195SCHEDULE 13G, 2026-07-312026-06-30
Dimensional Fund Advisors LP4.6%2,157,531SCHEDULE 13G/A, 2026-01-212025-12-31
Armistice Capital, LLC4.3%2,000,000SCHEDULE 13G/A, 2026-05-152026-03-31
T. Rowe Price Investment Management, Inc.3.7%1,703,510SCHEDULE 13G/A, 2026-05-072026-04-30
The Vanguard Group0%0SCHEDULE 13G/A, 2026-03-262026-03-13
RGM Capital, LLC0%0SCHEDULE 13G/A, 2026-02-132025-12-31
Reporting personSole votingShared votingSole dispositiveShared dispositiveFiling
Vanguard Capital Management350,40102,344,1950SCHEDULE 13G, 2026-07-31
Armistice Capital, LLC02,000,00002,000,000SCHEDULE 13G/A, 2026-05-15
Steven Boyd02,000,00002,000,000SCHEDULE 13G/A, 2026-05-15
T. Rowe Price Investment Management, Inc.1,680,45401,703,5100SCHEDULE 13G/A, 2026-05-07

The latest filing identifies Avanos Medical Inc by CUSIP 05350V106 and gives its principal executive office as 5405 Windward Parkway, Alpharetta, GA 30004 (SCHEDULE 13G, 2026-07-31).

FiledHolderPercentFiling
2025-07-29The Vanguard Group9.65%SCHEDULE 13G/A
2025-10-07T. Rowe Price Investment Management, Inc.10.2%SCHEDULE 13G/A
2025-10-09Dimensional Fund Advisors LP5.1%SCHEDULE 13G/A
2025-10-30The Vanguard Group7.38%SCHEDULE 13G/A
2025-11-14Armistice Capital, LLC5.39%SCHEDULE 13G
2026-01-21Dimensional Fund Advisors LP4.6%SCHEDULE 13G/A
2026-02-13RGM Capital, LLC0%SCHEDULE 13G/A
2026-02-17Armistice Capital, LLC6.89%SCHEDULE 13G/A
2026-03-26The Vanguard Group0%SCHEDULE 13G/A
2026-05-07T. Rowe Price Investment Management, Inc.11.5%SCHEDULE 13G/A
2026-05-07T. Rowe Price Investment Management, Inc.3.7%SCHEDULE 13G/A
2026-05-15Armistice Capital, LLC4.3%SCHEDULE 13G/A
2026-07-31Vanguard Capital Management5%SCHEDULE 13G
DateRecordFigureOur pageSource
July 30, 2026Leadership change: John S. Fischer appointed, General Counsel—Leadership changesSource

Hyperfine Inc

At 5% or more1
Filings2
Latest filing2026-07-28

Hyperfine Inc has 2 Schedule 13D or 13G filings on record since 2026-01-30. 1 holder's latest filing reports 5% or more of class a stock. Each figure below is the holder's own, as filed, with the filing linked.

HolderPercentSharesLatestEvent date
BlackRock, Inc.5.5%4,671,587SCHEDULE 13G, 2026-07-282026-06-30
The Vanguard Group4.34%3,568,038SCHEDULE 13G/A, 2026-01-302025-12-31
Reporting personSole votingShared votingSole dispositiveShared dispositiveFiling
BlackRock, Inc.4,605,42004,671,5870SCHEDULE 13G, 2026-07-28
The Vanguard Group0404,74403,568,038SCHEDULE 13G/A, 2026-01-30

The latest filing identifies Hyperfine Inc by CUSIP 44916K106 and gives its principal executive office as 351 New Whitfield Street, Guilford, CT 06437 (SCHEDULE 13G, 2026-07-28).

FiledHolderPercentFiling
2026-01-30The Vanguard Group4.34%SCHEDULE 13G/A
2026-07-28BlackRock, Inc.5.5%SCHEDULE 13G

Lensar, Inc.

At 5% or more1
Filings4
Latest filing2026-07-29

Lensar, Inc. has 4 Schedule 13D or 13G filings on record since 2025-10-17. 1 holder's latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.

HolderPercentSharesLatestEvent date
Brandes Investment Partners, LP8.5%1,026,018SCHEDULE 13G/A, 2026-05-142025-09-30
BlackRock, Inc.1.5%184,053SCHEDULE 13G/A, 2026-07-292026-06-30
Reporting personSole votingShared votingSole dispositiveShared dispositiveFiling
Brandes Investment Partners, LP0937,20701,026,018SCHEDULE 13G/A, 2026-05-14
BlackRock, Inc.183,7290184,0530SCHEDULE 13G/A, 2026-07-29

The latest filing identifies Lensar, Inc. by CUSIP 52634L108 and gives its principal executive office as 2800 DISCOVERY DRIVE SUITE 100, ORLANDO, FL 32826 (SCHEDULE 13G/A, 2026-07-29).

FiledHolderPercentFiling
2025-10-17BlackRock, Inc.5.2%SCHEDULE 13G
2025-11-13Brandes Investment Partners, LP6.5%SCHEDULE 13G
2026-05-14Brandes Investment Partners, LP8.5%SCHEDULE 13G/A
2026-07-29BlackRock, Inc.1.5%SCHEDULE 13G/A
DateRecordFigureOur pageSource
May 29, 2026Leadership change: Michael A. Rossi appointed, Chief Financial Officer—Leadership changesSource
April 15, 2026Leadership change: Thomas R. Staab departs, Chief Financial Officer—Leadership changesSource

Nano-X Imaging Ltd.

At 5% or more1
Filings4
Latest filing2026-10-29
Stated intents1

Nano-X Imaging Ltd. has 4 Schedule 13D or 13G filings on record since 2026-05-15. 1 holder's latest filing reports 5% or more of ordinary shares. Each figure below is the holder's own, as filed, with the filing linked.

Intent stated in Item 4 Moalem Moshe

The Reporting Person also intends to request that the Issuer refrain from issuing additional voting shares before the November 2, 2026 record date for that meeting.From Item 4 of the SCHEDULE 13D filed 2026-10-29
HolderPercentSharesLatestEvent date
Moalem Moshe8.49%6,675,413SCHEDULE 13D, 2026-10-292026-10-29
BlackRock, Inc.0.4%255,435SCHEDULE 13G/A, 2026-07-292026-06-30
SK square Co., Ltd.0%0SCHEDULE 13G/A, 2026-05-152026-03-31
Reporting personSole votingShared votingSole dispositiveShared dispositiveFiling
Moalem Moshe6,675,41306,675,4130SCHEDULE 13D, 2026-10-29
BlackRock, Inc.255,4350255,4350SCHEDULE 13G/A, 2026-07-29
SK square Co., Ltd.0000SCHEDULE 13G/A, 2026-05-15
SK Square Americas, Inc.0000SCHEDULE 13G/A, 2026-05-15

The latest filing identifies Nano-X Imaging Ltd. by CUSIP M70700105 and gives its principal executive office as Ofer Tech Park, 94 Shlomo Shmeltzer Road, Petach Tikva (SCHEDULE 13D, 2026-10-29).

The Ordinary Shares beneficially owned by the Reporting Person were acquired prior to and following the Issuer's initial public offering, using personal funds or through other transactions. No additional Ordinary Shares were acquired in connection with the filing of this Schedule 13D.Moalem Moshe, SCHEDULE 13D, 2026-10-29

Moalem Moshe

The Reporting Person acquired the Ordinary Shares beneficially owned by him for investment purposes and intends to review his investment in the Issuer on a continuing basis. The Reporting Person is dissatisfied with the Issuer's performance and the resulting impact on shareholder value. The Reporting Person intends to engage in discussions with the Issuer's management and Board of Directors (the "Board"), as well as other shareholders and interested parties, concerning the Issuer's business, operations, financial performance, strategy, management, corporate governance, Board composition and other matters relating to the Issuer. In particular, the Reporting Person opposes the proposed increase in the Issuer's authorized share capital from 150,000,000 to 450,000,000 Ordinary Shares described in the Issuer's proxy statement furnished to the Securities and Exchange Commission on October 28, 2026, for the special general meeting of shareholders scheduled for November 18, 2026. The Reporting Person is concerned about the scale of the proposed increase, its potential to facilitate substantial further dilution of existing shareholders, and the Issuer's financing strategy and capital allocation in light of its performance and the decline in the trading price of its Ordinary Shares. The Reporting Person currently intends to vote against that proposal and may communicate with the Issuer and other shareholders regarding his opposition. The Reporting Person also intends to request …The first part of Item 4 of the SCHEDULE 13D filed 2026-10-29; the filing has the rest
FiledHolderPercentFiling
2026-05-15SK square Co., Ltd.0%SCHEDULE 13G/A
2026-07-15Moalem Moshe7.56%SCHEDULE 13G/A
2026-07-29BlackRock, Inc.0.4%SCHEDULE 13G/A
2026-10-29Moalem Moshe intent stated8.49%SCHEDULE 13D

NeuroOne Medical Technologies Corporation

At 5% or more2
Filings5
Latest filing2026-07-14

NeuroOne Medical Technologies Corporation has 5 Schedule 13D or 13G filings on record since 2025-08-13. 2 holders' latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.

HolderPercentSharesLatestEvent date
Brian Pratt12.5%1,085,934SCHEDULE 13G/A, 2026-07-142026-07-10
Bleichroeder LP8.03%4,000,000SCHEDULE 13G, 2025-08-142025-06-30
Sio Capital Management, LLC4.72%2,360,635SCHEDULE 13G/A, 2025-11-122025-09-30
Reporting personSole votingShared votingSole dispositiveShared dispositiveFiling
Brian Pratt01,085,93401,085,934SCHEDULE 13G/A, 2026-07-14
Barbara Pratt01,085,93401,085,934SCHEDULE 13G/A, 2026-07-14
Bleichroeder LP4,000,00004,000,0000SCHEDULE 13G, 2025-08-14
Bleichroeder Holdings LLC4,000,00004,000,0000SCHEDULE 13G, 2025-08-14
Andew Gundlach4,000,00004,000,0000SCHEDULE 13G, 2025-08-14
Sio Capital Management, LLC02,360,63502,360,635SCHEDULE 13G/A, 2025-11-12

The latest filing identifies NeuroOne Medical Technologies Corporation by CUSIP 64130M308 and gives its principal executive office as 7599 Anagram Drive, Eden Prairie, MN 55344 (SCHEDULE 13G/A, 2026-07-14).

FiledHolderPercentFiling
2025-08-13Sio Capital Management, LLC7.07%SCHEDULE 13G
2025-08-14Bleichroeder LP8.03%SCHEDULE 13G
2025-11-12Sio Capital Management, LLC4.72%SCHEDULE 13G/A
2026-04-21Brian Pratt7.4%SCHEDULE 13G
2026-07-14Brian Pratt12.5%SCHEDULE 13G/A
DateRecordFigureOur pageSource
April 30, 2026Leadership change: Ronald McClurg departs, Chief Financial Officer—Leadership changesSource

Optex Systems Holdings Inc

At 5% or more1
Filings4
Latest filing2026-07-17

Optex Systems Holdings Inc has 4 Schedule 13D or 13G filings on record since 2025-07-11. 1 holder's latest filing reports 5% or more of com new. Each figure below is the holder's own, as filed, with the filing linked.

HolderPercentSharesLatestEvent date
Wasatch Advisors LP9.1%634,671SCHEDULE 13G/A, 2026-07-172026-06-30
Galileo Partners, LLC4.8%330,000SCHEDULE 13G/A, 2025-07-112025-06-23
Punch & Associates Investment Management, Inc.4.8%331,495SCHEDULE 13G/A, 2025-08-142025-06-30
Reporting personSole votingShared votingSole dispositiveShared dispositiveFiling
Wasatch Advisors LP505,9940634,6710SCHEDULE 13G/A, 2026-07-17
Galileo Partners, LLC330,000—330,000—SCHEDULE 13G/A, 2025-07-11
Punch & Associates Investment Management, Inc.331,4950331,4950SCHEDULE 13G/A, 2025-08-14

The latest filing identifies Optex Systems Holdings Inc by CUSIP 68384X209 and gives its principal executive office as 1420 Presidential Drive, Richardson, TX 75081 (SCHEDULE 13G/A, 2026-07-17).

FiledHolderPercentFiling
2025-07-11Galileo Partners, LLC4.8%SCHEDULE 13G/A
2025-08-14Punch & Associates Investment Management, Inc.4.8%SCHEDULE 13G/A
2026-04-22Wasatch Advisors LP5.7%SCHEDULE 13G
2026-07-17Wasatch Advisors LP9.1%SCHEDULE 13G/A
DateRecordFigureOur pageSource
June 17, 2026Leadership change: Karen Hawkins departs, Chief Financial Officer, and 1 more—Leadership changesSource

Procept Biorobotics Corp

At 5% or more3
Filings10
Latest filing2026-10-30

Procept Biorobotics Corp has 10 Schedule 13D or 13G filings on record since 2025-11-14. 3 holders' latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.

HolderPercentSharesLatestEvent date
BlackRock, Inc.8.2%4,646,656SCHEDULE 13G/A, 2026-07-292026-06-30
T. Rowe Price Investment Management, Inc.5.9%3,271,408SCHEDULE 13G, 2026-02-172025-12-31
BNP Paribas Asset Management Holding S.A.5.5%3,094,649SCHEDULE 13G, 2026-02-112025-12-31
Vanguard Capital Management4.96%2,845,781SCHEDULE 13G/A, 2026-10-302026-09-30
Fmr LLC2.9%1,610,138SCHEDULE 13G/A, 2026-03-062026-02-27
AllianceBernstein L.P.0.3%147,327SCHEDULE 13G/A, 2026-05-182026-03-31
The Vanguard Group0%0SCHEDULE 13G/A, 2026-03-272026-03-13
Reporting personSole votingShared votingSole dispositiveShared dispositiveFiling
BlackRock, Inc.4,558,57104,646,6560SCHEDULE 13G/A, 2026-07-29
Vanguard Capital Management433,13002,845,7810SCHEDULE 13G/A, 2026-10-30
AllianceBernstein L.P.146,0270147,3270SCHEDULE 13G/A, 2026-05-18
The Vanguard Group0000SCHEDULE 13G/A, 2026-03-27

The latest filing identifies Procept Biorobotics Corp by CUSIP 74276L105 and gives its principal executive office as 150 Baytech Drive, San Jose, CA 95134 (SCHEDULE 13G/A, 2026-10-30).

FiledHolderPercentFiling
2025-11-14AllianceBernstein L.P.6.1%SCHEDULE 13G
2026-01-08Fmr LLC8.3%SCHEDULE 13G/A
2026-02-11BNP Paribas Asset Management Holding S.A.5.5%SCHEDULE 13G
2026-02-17T. Rowe Price Investment Management, Inc.5.9%SCHEDULE 13G
2026-03-06Fmr LLC2.9%SCHEDULE 13G/A
2026-03-27The Vanguard Group0%SCHEDULE 13G/A
2026-04-30Vanguard Capital Management5%SCHEDULE 13G
2026-05-18AllianceBernstein L.P.0.3%SCHEDULE 13G/A
2026-07-29BlackRock, Inc.8.2%SCHEDULE 13G/A
2026-10-30Vanguard Capital Management4.96%SCHEDULE 13G/A
DateRecordFigureOur pageSource
October 2, 2026Leadership change: Michael Mack appointed, Director—Leadership changesSource

Teradyne Inc

At 5% or more3
Filings6
Latest filing2026-07-30

Teradyne Inc has 6 Schedule 13D or 13G filings on record since 2025-07-29. 3 holders' latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.

HolderPercentSharesLatestEvent date
BlackRock, Inc.11.1%17,452,401SCHEDULE 13G/A, 2026-07-302026-06-30
Vanguard Capital Management7.49%11,732,982SCHEDULE 13G, 2026-04-292026-03-31
Vanguard Portfolio Management5.5%8,623,026SCHEDULE 13G, 2026-04-292026-03-31
The Vanguard Group0%0SCHEDULE 13G/A, 2026-03-272026-03-13
Reporting personSole votingShared votingSole dispositiveShared dispositiveFiling
BlackRock, Inc.16,414,299017,452,4010SCHEDULE 13G/A, 2026-07-30
Vanguard Capital Management1,556,791011,732,9820SCHEDULE 13G, 2026-04-29
Vanguard Portfolio Management20,10808,623,0260SCHEDULE 13G, 2026-04-29

The latest filing identifies Teradyne Inc by CUSIP 880770102 and gives its principal executive office as 600 RIVERPARK DRIVE, NORTH READING, MA 01864 (SCHEDULE 13G/A, 2026-07-30).

FiledHolderPercentFiling
2025-07-29The Vanguard Group13.07%SCHEDULE 13G/A
2026-03-27The Vanguard Group0%SCHEDULE 13G/A
2026-04-29Vanguard Capital Management7.49%SCHEDULE 13G
2026-04-29Vanguard Portfolio Management5.5%SCHEDULE 13G
2026-06-04BlackRock, Inc.10.1%SCHEDULE 13G/A
2026-07-30BlackRock, Inc.11.1%SCHEDULE 13G/A

Trane Technologies Plc

At 5% or more3
Filings5
Latest filing2026-07-27

Trane Technologies Plc has 5 Schedule 13D or 13G filings on record since 2025-11-05. 3 holders' latest filing reports 5% or more of ordinary shares, par value $1.00 per share. Each figure below is the holder's own, as filed, with the filing linked.

HolderPercentSharesLatestEvent date
Vanguard Capital Management7.49%16,581,171SCHEDULE 13G, 2026-04-282026-03-31
Jpmorgan Chase & Co.5.6%12,451,325SCHEDULE 13G/A, 2026-07-272026-06-30
Fmr LLC5.1%11,368,697SCHEDULE 13G, 2025-11-052025-09-30
The Vanguard Group0%0SCHEDULE 13G/A, 2026-03-262026-03-13
Reporting personSole votingShared votingSole dispositiveShared dispositiveFiling
Vanguard Capital Management2,198,423016,581,1710SCHEDULE 13G, 2026-04-28
Jpmorgan Chase & Co.11,187,605130,07912,389,59960,399SCHEDULE 13G/A, 2026-07-27
The Vanguard Group0000SCHEDULE 13G/A, 2026-03-26

The latest filing identifies Trane Technologies Plc by CUSIP G8994E103 and gives its principal executive office as 170/175 Lakeview Dr., Airside Business Park, Swords Co. Dublin (SCHEDULE 13G/A, 2026-07-27).

FiledHolderPercentFiling
2025-11-05Fmr LLC5.1%SCHEDULE 13G
2026-01-23Jpmorgan Chase & Co.7.3%SCHEDULE 13G/A
2026-03-26The Vanguard Group0%SCHEDULE 13G/A
2026-04-28Vanguard Capital Management7.49%SCHEDULE 13G
2026-07-27Jpmorgan Chase & Co.5.6%SCHEDULE 13G/A
DateRecordFigureOur pageSource
July 22, 2026Leadership change filing (Form 8-K, Item 5.02)—Leadership changesSource
June 10, 2026Leadership change: Donald E. Simmons appointed, Chief Operating Officer—Leadership changesSource

Where this comes from

Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.

Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.

All 5%+ stakes

RSS